Navigation Links
Hill-Rom Selects NanoHorizons to Provide Antimicrobial Protection for Hill-Rom Products Using Nanotechnology
Date:3/6/2008

ficers and other key personnel, and certain tax-related matters. For a more in depth discussion of these and other factors that could cause actual results to differ from those contained in forward-looking statements, see the discussions under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the period ended September 30, 2007 and in Amendment 1 to the Batesville Holdings, Inc., Form 10. The Company assumes no obligation to update or revise any forward-looking statements.

(1) http://www.cdc.gov/ncidod/dhqp/pdf/guidelines/Enviro_guide_03.pdf

(2) http://www.cdc.gov/ncidod/dhqp/hai.html

Hill-Rom Media:

Lauren Green-Caldwell, Director, Corporate Communications & Public Relations
Phone: 812-934-8692

Email: lauren.green-caldwell@hillenbrand.com

Hill-Rom Investor Relations:

Blair A. (Andy) Rieth, Jr., Vice President, Investor Relations, Corporate Communications & Global Brand Development, Hillenbrand Industries, Inc.

Phone: 812-931-2199

Email: andy.rieth@hillenbrand.com


'/>"/>
SOURCE Hillenbrand Industries, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Hospitals Could Improve Outcomes for Patients and Save Millions According to Hill-Rom 10th Annual Pressure Ulcer Survey
2. Hill-Rom Announces Singapore Will Be Site for Asia-Pacific Innovation Center
3. Hill-Rom Introduces Fashionable, Affordable Bed for Home and Post-Acute Care Patients
4. Cerner Corporation and Hill-Rom Partner to Unify Hospital Care Delivery
5. Mindray Selects Actel Low-Power Flash FPGAs for Demanding Medical Equipment Applications
6. Purdue Pharma Selects Systech to Provide Sustainable Infrastructure for Serialization
7. Loma Linda University Medical Center Selects Beryl to Manage Call Center Interactions for Womens Services Programs and Departments
8. West Penn Allegheny Health System Selects Electronic Health Record From Allscripts
9. ABMS Selects Kevin B. Weiss, MD, MPH, as New President and CEO
10. NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration
11. Moffitt Selects Microsofts Azyxxi to Help Drive Personalized Cancer Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Empire BlueCross BlueShield Appoints Chief Medical Officer 2Health News:'Positively Conscious: An Enlightened Look At Life' 2Health News:PatentStorm Releases U.S. Patent Applications and Other Features 2Health News:Former Mayor of Indianapolis to Serve as a Senior Strategic Advisor to McKenna Long & Aldridge LLP's Global Infrastructure Finance and Public-Private Partnerships Practice 2Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 2Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 3Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 4Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 5Health News:Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG 2Health News:Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG 3Health News:Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG 4
Breaking Medicine Technology:Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 2Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 3Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 4Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 5Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 6Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 7Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 8Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 9Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 2Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 3Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 4Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 5Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 6Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 7Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 8Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 9Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 2Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 3Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 4Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 5Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 6Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 7Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 8Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 9Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 10Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 11Nearly 9 in 10 Seniors Satisfied With Medigap 48743 1Nearly 9 in 10 Seniors Satisfied With Medigap 48743 2Nearly 9 in 10 Seniors Satisfied With Medigap 48743 3A Robot That Reads Your Mind 3F 48740 1A Robot That Reads Your Mind 3F 48740 2The Stress of Sudden Fame Made Anxiety Attacks Headline News 48736 1The Stress of Sudden Fame Made Anxiety Attacks Headline News 48736 2
Other Medicine Technology:New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 2New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 3New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 4New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 5New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 6New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 7U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 2U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 3U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 4U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 5